Beyond tissue specimen, a recent study using digital sequencing of ctDNAs from 438 patients analyzed clinical associations of MET alterations in the plasma of patients with diverse malignancies including NSCLC and showed that MET ctDNA alterations were associated with a poorer prognosis, higher numbers of genomic abnormalities, and bone metastases. Here, MET is linked to non-small cell lung carcinoma.